Compare CIX & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CIX | FHTX |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.5M | 247.1M |
| IPO Year | 1998 | 2020 |
| Metric | CIX | FHTX |
|---|---|---|
| Price | $23.51 | $5.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $11.43 |
| AVG Volume (30 Days) | 14.4K | ★ 168.3K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 9.77% | N/A |
| EPS Growth | ★ 2.86 | N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $159,004,000.00 | $24,518,000.00 |
| Revenue This Year | N/A | $47.50 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.36 | ★ N/A |
| Revenue Growth | ★ 5.52 | N/A |
| 52 Week Low | $17.89 | $2.95 |
| 52 Week High | $32.30 | $6.79 |
| Indicator | CIX | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 67.38 |
| Support Level | $20.29 | $4.21 |
| Resistance Level | $24.62 | $4.59 |
| Average True Range (ATR) | 0.92 | 0.29 |
| MACD | 0.24 | 0.07 |
| Stochastic Oscillator | 54.04 | 79.10 |
Compx International Inc is a manufacturer of security products. Its security products are used in recreational transportation, postal, office & institutional furniture, cabinetry, tool storage, healthcare, and a variety of other industries. Also, it is engaged in the manufacturing of stainless steel exhaust systems, gauges, throttle controls, and trim tabs for the recreational marine industry. The company's operating segment includes Security Products and Marine Components. The company generates maximum revenue from the Security Products segment, which manufactures mechanical and electrical cabinet locks and other locking mechanisms. Its geographical segments are the United States, Canada, Mexico, and others, of which the United States accounts for the vast majority of revenue.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.